pertuzumab
Roche Q2 Pharmaceutical Revenues Increase 4 Percent
Increasing revenues from newer oncology drugs like atezolizumab and strong diagnostics division revenues helped diminish the impact of the pandemic.
Genentech Basket Trial Identifies Impact of Co-Mutations in Dual HER2-Targeted Treatment Response
Researchers studying Perjeta and Herceptin in HER2-positive advanced solid tumors reported that the combination is efficacious in KRAS wild-type tumors.
Genentech Garners FDA Approval for Skin-Injectable Phesgo in HER2-Positive Breast Cancer
Healthcare professionals can inject the regimen, containing Perjeta, Herceptin, and hyaluronidase, in patients' homes after intravenous chemotherapy.
The study showed that patients with targetable genomic markers, especially HER2 alterations, responded well to chemotherapy-free treatments.
Colorectal Cancer Patients Benefit from Biomarker-Guided Treatments in TAPUR Study
Benefit was seen for patients with high TMB on Keytruda, with ERBB2 amplifications on Perjeta and Herceptin, and with BRAF mutations on Cotellic plus Zelboraf.